{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:08:27Z","timestamp":1773238107021,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s10549-005-9069-8","type":"journal-article","created":{"date-parts":[[2005,11,30]],"date-time":"2005-11-30T11:16:16Z","timestamp":1133349376000},"page":"123-129","source":"Crossref","is-referenced-by-count":4,"title":["Use of raloxifene among women with a history of breast cancer"],"prefix":"10.1007","volume":"96","author":[{"given":"Laurel A.","family":"Habel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Pressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Sidney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty","family":"Suh-Burgmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Fehrenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles P.","family":"Quesenberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,1]]},"reference":[{"issue":"7","key":"9069_CR1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, 1994; Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14J Natl Cancer Inst 86(7): 527\u2013537","journal-title":"J Natl Cancer Inst"},{"key":"9069_CR2","unstructured":"Cruzan SM: FDA Approves Raloxifene to Prevent Osteoporosis. 2005. 5-20-0005. http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/ANS000838.html"},{"key":"9069_CR3","unstructured":"Drug Approvals for September 1999: US Food and Drug Administration. Center for Drug Evaluation and Research. 2005. http:\/\/www.fda.gov\/cder\/da\/da\/0999.htm"},{"issue":"23","key":"9069_CR4","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al., 1999; The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene EvaluationJAMA 281(23):2189\u20132197","journal-title":"JAMA"},{"issue":"23","key":"9069_CR5","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","volume":"96","author":"S Martino","year":"2004","unstructured":"Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al., 2004; Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifeneJ Natl Cancer Inst 96(23):1751\u20131761","journal-title":"J Natl Cancer Inst"},{"key":"9069_CR6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1749-6632.2001.tb04036.x","volume":"949","author":"E Barrett-Connor","year":"2001","unstructured":"Barrett-Connor E, 2001; Raloxifene: risks and benefitsAnn NY Acad Sci 949:295\u2013303","journal-title":"Ann NY Acad Sci"},{"key":"9069_CR7","unstructured":"Study of Tamoxifen and Raloxifene (STAR) Trial: 2005. http:\/\/www.cancer.gov\/star"},{"issue":"4","key":"9069_CR8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0002-9149(01)01685-X","volume":"88","author":"L Mosca","year":"2001","unstructured":"Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, et al., 2001; Design and methods of the Raloxifene Use for The Heart (RUTH) studyAm J Cardiol 88(4):392\u2013395","journal-title":"Am J Cardiol"},{"issue":"19","key":"9069_CR9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/jnci\/93.19.1449","volume":"93","author":"VC Jordan","year":"2001","unstructured":"Jordan VC, Gapstur S, Morrow M, 2001; Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart diseaseJ Natl Cancer Inst 93(19):1449\u20131457","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"9069_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ki.1982.133","volume":"22","author":"RA Hiatt","year":"1982","unstructured":"Hiatt RA, Friedman GD, 1982; The frequency of kidney and urinary tract diseases in a defined populationKidney Int 22(1):63\u201368","journal-title":"Kidney Int"},{"key":"9069_CR11","first-page":"19","volume":"12","author":"NP Gordon","year":"1991","unstructured":"Gordon NP, Kaplan GA, 1991; Some evidence refuting the HMO \u201cfavorable selection\u201d hypothesis: the case of Kaiser PermanenteAdv Health Econ Health Serv Res 12:19\u201339","journal-title":"Adv Health Econ Health Serv Res"},{"issue":"5","key":"9069_CR12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2105\/AJPH.82.5.703","volume":"82","author":"N Krieger","year":"1992","unstructured":"Krieger N, 1992; Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology Am J Public Health 82(5):703\u2013710","journal-title":"Am J Public Health"},{"key":"9069_CR13","unstructured":"Breslow NE, Day NE: Statistical Methods in Cancer Research. 1980"},{"issue":"7","key":"9069_CR14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al., 1999; Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA 282(7):637\u2013645","journal-title":"JAMA"},{"issue":"18","key":"9069_CR15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","volume":"279","author":"BW Walsh","year":"1998","unstructured":"Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al., 1998; Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal womenJAMA 279(18):1445\u20131451","journal-title":"JAMA"},{"issue":"1","key":"9069_CR16","first-page":"214","volume":"85","author":"BW Walsh","year":"2000","unstructured":"Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, et al., 2000; The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trialJ Clin Endocrinol Metab 85(1):214\u2013218","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"9069_CR17","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E","volume":"88","author":"W Gradishar","year":"2000","unstructured":"Gradishar W, Glusman J, Lu Y, Vogel C, Cohen FJ, Sledge GW, Jr., 2000; Effects of high dose raloxifene in selected patients with advanced breast carcinomaCancer 88(9):2047\u20132053","journal-title":"Cancer"},{"issue":"9","key":"9069_CR18","first-page":"961","volume":"10","author":"M Dowsett","year":"2001","unstructured":"Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, et al., 2001; Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patientsCancer Epidemiol Biomarkers Prev 10(9):961\u2013966","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"9069_CR19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jnci\/94.4.274","volume":"94","author":"RM O\u2019Regan","year":"2002","unstructured":"O\u2019Regan RM, Gajdos C, Dardes RC, De Los RA, Park W, Rademaker AW, et al., 2002; Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic miceJ Natl Cancer Inst 94(4):274\u2013283","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"9069_CR20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, Wolmark N, 2001; Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trialJ Natl Cancer Inst 93(9):684\u2013690","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"9069_CR21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/jnci\/94.4.242","volume":"94","author":"MB Sporn","year":"2002","unstructured":"Sporn MB, 2002; Hobson\u2019s choice and the need for combinations of new agents for the prevention and treatment of breast cancerJ Natl Cancer Inst 94(4):242\u2013243","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"9069_CR22","first-page":"1385","volume":"18","author":"PM Ravdin","year":"2004","unstructured":"Ravdin PM, 2004; Managing the risk of osteoporosis in women with a history of early breast cancerOncology (Huntingt) 18(11):1385\u20131390, 1393","journal-title":"Oncology (Huntingt)"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-005-9069-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-005-9069-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-005-9069-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:29:30Z","timestamp":1559219370000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-005-9069-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["9069"],"URL":"https:\/\/doi.org\/10.1007\/s10549-005-9069-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}